ATR Inhibitor IV

A cell-permeable phenylpyrazine derivative that acts as a potent, ATP-competitive (K_i= 13 nM; IC₅₀/[ATP] = 70 nM/50 µM and 128 nM/100 µM), ATR-selective inhibitor with much reduced or little potency against 4 related PIKKs (K_i= 2.2, 3.9, 16, and >1 µM, respectively, against DNA-PK, PI 3-Kγ, ATM, and mTOR) and 50 other kinases. Shown to selectively inhibit ATR-dependent H2AX Ser139 & Chk1 Ser345 phosphorylation (complete inhibition at 10 µM in HT29 and HFL1 cultures) without affecting ATM- and DNA-PK-mediated H2AX or ATM-mediated Chk2 phosphorylation. Short-term (24 h) VE-821 treatment, either alone or in synergy with Cisplatin (Cat. No. 232120), results in reversible cytostatic growth arrest regardless of cellular ATM-p53 pathway activity, while cytotoxicity and Cisplatin synergism in cell death induction is reported to occur only upon long-term VE-821 exposure (≥72 h) in cultures with ATM-p53 pathway defects.Please note that the molecular weight for this compound is batch-specific due to variable water content.

Cell permeable: yes

Reversible: yes

Packaged under inert gas

Prevo, R., et al. 2012, Cancer Biol. Ther.13, 1072; Pires, I.M., et al. 2012, Br. J. Cancer107, 291; Reaper, P.M., et al. 2011, Nat. Chem. Biol.7, 428.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Toxicity: Standard Handling (A)